Our strategy is to develop herpesvirus-based vaccines for use in animals to protect them against infectious disease.
These diseases include both economically important livestock diseases, such as coliform mastitis in cattle, African Swine Fever and PRRS in pigs, and zoonotic diseases that are transferred from animals to humans, such as Lassa fever, tuberculosis and Streptococcus suis.
Most emerging infections, especially those with high pandemic potential in humans, originate from domestic and wildlife animal populations. Due to the ability to test animal vaccines in their target host relatively early in the development process, and the relative speed at which animal compared to human vaccines are approved, our approach is highly aligned with zoonotic disease control.
Through collaboration with several research groups, a suite of tuneable herpes virus-based vector vaccines have been developed to address specific pathogen needs. These are based on cytomegaloviruses (CMV) and bovine herpesvirus-4 (BoHV-4). The attributes of the platform allow vaccines to specifically target both B and T cell immunity, allow multigene insertion and expression, and promote high quality immunological responses over prolonged periods post-immunisation.
We use cutting edge molecular techniques to create our vaccines. We are able to progress from a gene target to stocks of vaccine ready for trials in 6 months.
Other platform attributes include:
BoHV-4 and CMV also have different benefits as described.